Cybin provides progress update on its cyb004-e phase 1 trial

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing psychedelics to therapeutics®, is pleased to announce that its cyb004-e phase 1 trial evaluating n,n-dimethyltryptamine (“dmt”) has completed dosing for four out of five participant cohorts and the safety review committee has confirmed no clinically significant safety or tolerability issues.
CYBN Ratings Summary
CYBN Quant Ranking